https://www.pharmaradar360.com/article/tegoprubart-sustains-increased-egfr-longterm-compared-to-tacrolimus-be16f06d6881492aPharma Surgeen2026-07-15T16:15:46.000ZTegoprubart Sustains Increased eGFR Longterm Compared to Tacrolimushttps://www.pharmaradar360.com/article/all-12-tegoprubart-recipients-off-external-insulin-following-islet-implant-in-pi-0915a22e754731f4Pharma Surgeen2026-07-15T16:15:18.000ZAll 12 Tegoprubart Recipients Off External Insulin Following Islet Implant in Pilot Studyhttps://www.pharmaradar360.com/article/cannara-biotech-reports-q3-2026-results-full-earnings-call-transcript-9aa3d94668d043c3Pharma Surgeen2026-07-15T15:58:43.000ZCannara Biotech Reports Q3 2026 Results: Full Earnings Call Transcripthttps://www.pharmaradar360.com/article/braveheart-attovia-join-next-wave-of-biotech-ipos-004367ddce29b346Pharma Surgeen2026-07-15T15:53:55.000ZBraveheart, Attovia join next wave of biotech IPOshttps://www.pharmaradar360.com/article/cervomed-reports-positive-clinical-biomarker-and-mri-data-for-neflamapimod-at-aa-1728d74cea19da4fPharma Surgeen2026-07-15T15:51:26.000ZCervoMed Reports Positive Clinical, Biomarker and MRI Data for Neflamapimod at AAIC 2026https://www.pharmaradar360.com/article/q-a-how-pharma-3pl-is-evolving-beyond-the-pallet-be2e59931753a28ePharma Surgeen2026-07-15T15:49:50.000ZQ&A: How Pharma 3PL Is Evolving Beyond the Pallethttps://www.pharmaradar360.com/article/adhd-medicines-prescriptions-rose-again-in-2025-8c8f30c58bd50c8fPharma Surgeen2026-07-15T15:48:54.000ZADHD medicines prescriptions rose again in 2025https://www.pharmaradar360.com/article/johnson-fistel-pllp-investigates-claims-on-behalf-of-e738e7669e497667Pharma Surgeen2026-07-15T15:33:28.000ZJohnson Fistel, PLLP Investigates Claims on Behalf ofhttps://www.pharmaradar360.com/article/astrazeneca-licenses-novel-oral-egfr-inhibitor-for-1-5bn-f61e6125381427bePharma Surgeen2026-07-15T15:30:05.000ZAstraZeneca licenses novel oral EGFR inhibitor for $1.5bnhttps://www.pharmaradar360.com/article/india-s-sun-pharma-wins-south-africa-approval-to-launch-generic-ozempic-e07e1258d3a6fd4aPharma Surgeen2026-07-15T15:30:01.000ZIndia's Sun Pharma wins South Africa approval to launch generic Ozempichttps://www.pharmaradar360.com/article/stoppering-machines-market-growth-outlook-to-2035-automation-and-biologics-fuel-2df6d3b9f8473491Pharma Surgeen2026-07-15T15:16:12.000ZStoppering Machines Market Growth Outlook to 2035: Automation and Biologics Fuel Demand - News and Statisticshttps://www.pharmaradar360.com/article/soficitinib-icp-332-meets-primary-endpoint-in-phase-3-trial-for-moderate-to-seve-1e06ae02dd554ec7Pharma Surgeen2026-07-15T15:11:15.000ZSoficitinib (ICP-332) Meets Primary Endpoint in Phase 3 Trial for Moderate to Severe ADhttps://www.pharmaradar360.com/article/j-j-raises-fy26-outlook-following-positive-q2-bf5ed898f58b39e8Pharma Surgeen2026-07-15T15:11:15.000ZJ&J raises FY26 outlook following positive Q2https://www.pharmaradar360.com/article/celcuity-s-breast-cancer-drug-approved-its-first-6bbba6e0d08aa5a4Pharma Surgeen2026-07-15T15:09:37.000ZCelcuity’s breast cancer drug approved, its firsthttps://www.pharmaradar360.com/article/pitt-signs-deal-with-biotech-firm-to-study-mitochondria-in-space-and-long-covid-a36d20a6cf68f495Pharma Surgeen2026-07-15T15:08:56.000ZPitt signs deal with biotech firm to study mitochondria in space and long Covidhttps://www.pharmaradar360.com/article/the-glp-1-boom-created-a-2-billion-opening-in-aesthetics-one-preclinical-biotech-0e28cbf91787f51dPharma Surgeen2026-07-15T15:01:00.000ZThe GLP-1 Boom Created a $2 Billion Opening in Aesthetics. One Preclinical Biotech Is Building the Product to Fill It.https://www.pharmaradar360.com/article/big-pharma-backed-advancell-flush-with-315m-series-d-ready-to-put-radiotherapy-p-323618edfa7cd7e3Pharma Surgeen2026-07-15T14:50:46.000ZBig Pharma-backed AdvanCell, flush with $315M series D, ready to put radiotherapy pedal to the metalhttps://www.pharmaradar360.com/article/fda-finalizes-guidance-on-psychedelic-drug-clinical-trial-design-and-safety-cons-43f626bb37f0f589Pharma Surgeen2026-07-15T14:48:45.000ZFDA finalizes guidance on psychedelic drug clinical trial design and safety considerationshttps://www.pharmaradar360.com/article/doj-s-bulk-sensitive-personal-data-rule-a-cross-border-compliance-imperative-for-2b077597d354c170Pharma Surgeen2026-07-15T14:46:55.000ZDOJ’s Bulk Sensitive Personal Data Rule: A Cross-Border Compliance Imperative for the Life Sciences Industryhttps://www.pharmaradar360.com/article/katalyze-ai-raises-10-5m-to-build-the-agentic-operating-system-for-pharmaceutica-d0d0e926641d8721Pharma Surgeen2026-07-15T14:41:17.000ZKatalyze AI Raises $10.5M to Build the Agentic Operating System for Pharmaceutical Companieshttps://www.pharmaradar360.com/article/why-this-biotech-stock-with-its-first-fda-approval-just-crashed-by-double-digits-32f9d1445f954682Pharma Surgeen2026-07-15T14:26:00.000ZWhy This Biotech Stock, With Its First FDA Approval, Just Crashed By Double Digitshttps://www.pharmaradar360.com/article/tukaram-mundhe-effect-fda-turns-to-ai-for-instant-food-adulteration-fake-med-com-22c8b6fd3870bdedPharma Surgeen2026-07-15T14:19:50.000ZTukaram Mundhe Effect: FDA Turns To AI For Instant Food Adulteration, Fake Med Complaintshttps://www.pharmaradar360.com/article/manufacturing-intelligence-sizing-up-pharma-s-biggest-ai-deals-part-one-fd009a9aff191c9cPharma Surgeen2026-07-15T14:19:19.000ZManufacturing Intelligence: Sizing Up Pharma's Biggest AI Deals, Part Onehttps://www.pharmaradar360.com/article/china-targets-pharmaceutical-supply-chains-in-coordinated-fraud-inspections-f6023655e9bafec9Pharma Surgeen2026-07-15T14:11:51.000ZChina targets pharmaceutical supply chains in coordinated fraud inspectionshttps://www.pharmaradar360.com/article/merck-to-present-hiv-treatment-trial-data-at-aids-conference-by-investing-com-9583a342e41b94e1Pharma Surgeen2026-07-15T14:06:22.000ZMerck to present HIV treatment trial data at AIDS conference By Investing.comhttps://www.pharmaradar360.com/article/women-s-health-attracted-record-equity-in-2025-as-companies-share-capital-422518965fff7c03Pharma Surgeen2026-07-15T14:02:18.000ZWomen’s health attracted record equity in 2025 as companies share capitalhttps://www.pharmaradar360.com/article/review-body-on-doctors-and-dentists-remuneration-remit-letter-2027-to-2028-8c7b12beaeebe78aPharma Surgeen2026-07-15T13:57:34.000ZReview Body on Doctors' and Dentists' Remuneration remit letter: 2027 to 2028https://www.pharmaradar360.com/article/nhs-pay-review-body-remit-letter-2027-to-2028-6a81d0c8fb23dc5aPharma Surgeen2026-07-15T13:57:31.000ZNHS Pay Review Body remit letter: 2027 to 2028https://www.pharmaradar360.com/article/senior-salaries-review-body-remit-letter-2027-to-2028-4b88fe34e0bf692bPharma Surgeen2026-07-15T13:57:27.000ZSenior Salaries Review Body remit letter: 2027 to 2028https://www.pharmaradar360.com/article/clinical-trials-for-medicines-ending-a-clinical-trial-e20295b3d49b69b5Pharma Surgeen2026-07-15T13:50:10.000ZClinical trials for medicines: ending a clinical trialhttps://www.pharmaradar360.com/article/gsk-completes-acquisition-of-nuvalent-inc-bb9f750c34ca10f4Pharma Surgeen2026-07-15T13:40:11.000ZGSK completes acquisition of Nuvalent, Inc.https://www.pharmaradar360.com/article/smarter-data-faster-decisions-how-biotech-funding-pressures-are-reshaping-clinic-bd8b5260d7a79d75Pharma Surgeen2026-07-15T13:39:08.000ZSmarter data, faster decisions: How biotech funding pressures are reshaping clinical developmenthttps://www.pharmaradar360.com/article/explained-7-major-fda-crackdowns-in-pune-under-tukaram-mundhe-from-blood-banks-t-9aca8b1007caf94aPharma Surgeen2026-07-15T13:35:50.000ZExplained: 7 Major FDA Crackdowns In Pune Under Tukaram Mundhe, From Blood Banks To Counterfeit Cetaphil Skinhttps://www.pharmaradar360.com/article/akeso-opens-u-s-phase-ii-trial-for-pd-1-ctla-4-bispecific-42106c875062cb91Pharma Surgeen2026-07-15T13:30:48.000ZAkeso Opens U.S. Phase II Trial for PD-1/CTLA-4 Bispecifichttps://www.pharmaradar360.com/article/american-airlines-cargo-builds-pharma-corridor-connecting-europe-and-the-us-0ded2e328f0fe503Pharma Surgeen2026-07-15T13:27:41.000ZAmerican Airlines Cargo builds pharma corridor connecting Europe and the UShttps://www.pharmaradar360.com/article/aaic26-the-role-of-biomarkers-in-primary-care-and-early-diagnostics-5a68a22c09a0dee2Pharma Surgeen2026-07-15T13:25:18.000ZAAIC26: The role of biomarkers in primary care and early diagnosticshttps://www.pharmaradar360.com/article/global-biopharmaceutical-ceos-response-to-reforms-introduced-in-germany-22d462cb40892ca1Pharma Surgeen2026-07-15T13:14:50.000ZGlobal biopharmaceutical CEOs response to reforms introduced in Germanyhttps://www.pharmaradar360.com/article/fda-activity-round-up-july-2026-8f9dcbf0475c8f26Pharma Surgeen2026-07-15T13:04:19.000ZFDA Activity Round Up – July 2026https://www.pharmaradar360.com/article/fda-drug-approval-affects-healthcare-around-the-world-but-political-shortcuts-co-f9033f1952aabaeaPharma Surgeen2026-07-15T13:04:08.000ZFDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputationhttps://www.pharmaradar360.com/article/botulinum-toxin-type-a-products-updated-warnings-regarding-risk-of-iatrogenic-bo-fd0eebf65ce9495cPharma Surgeen2026-07-15T13:00:15.000ZBotulinum toxin type A products: updated warnings regarding risk of iatrogenic botulismhttps://www.pharmaradar360.com/article/cellular-intelligence-expands-leadership-team-with-seasoned-ai-and-biotech-indus-d48bfba9c9d35885Pharma Surgeen2026-07-15T13:00:00.000ZCellular Intelligence Expands Leadership Team with Seasoned AI and Biotech Industry Executiveshttps://www.pharmaradar360.com/article/kelun-biotech-reports-phase-iii-success-for-sac-tmt-combination-in-nsclc-07ad02e41eb33b24Pharma Surgeen2026-07-15T12:57:05.000ZKelun-Biotech reports Phase III success for sac-TMT combination in NSCLChttps://www.pharmaradar360.com/article/acrp-certification-exams-transition-to-ich-e6-r3-on-july-15-65c21fd4115ed5bePharma Surgeen2026-07-15T12:48:26.000ZACRP Certification Exams Transition to ICH E6(R3) on July 15https://www.pharmaradar360.com/article/a-weight-loss-revolution-is-reshaping-bodies-this-preclinical-biotech-wants-to-b-c395289e70b82450Pharma Surgeen2026-07-15T12:45:10.000ZA Weight-Loss Revolution Is Reshaping Bodies. This Preclinical Biotech Wants to Build What Comes Nexthttps://www.pharmaradar360.com/article/atrium-therapeutics-launches-phase-1-2-trial-for-atr-1072-f198b77f4f7587c7Pharma Surgeen2026-07-15T12:22:28.000ZAtrium Therapeutics Launches Phase 1/2 Trial for ATR 1072https://www.pharmaradar360.com/article/fda-drug-approval-affects-healthcare-around-the-world-but-political-shortcuts-co-d894081a500d9faePharma Surgeen2026-07-15T12:09:59.000ZFDA drug approval affects healthcare around the world, but political shortcuts could hurt the agency’s international reputationhttps://www.pharmaradar360.com/article/surveillance-of-bloodstream-infections-in-intensive-care-units-england-2025-80263adc565cf040Pharma Surgeen2026-07-15T12:07:26.000ZSurveillance of bloodstream infections in intensive care units, England: 2025https://www.pharmaradar360.com/article/segunda-reunion-de-2026-del-comite-de-seguridad-de-medicamentos-veterinarios-y-d-624354da3256518ePharma Surgeen2026-07-15T12:06:01.000ZSegunda reunión de 2026 del Comité de Seguridad de Medicamentos Veterinarios y del Comité Técnico del Sistema Español de Farmacovigilancia de Medicamentos Veterinarioshttps://www.pharmaradar360.com/article/guidance-medical-devices-list-of-uk-approved-bodies-282ee766885a0ff9Pharma Surgeen2026-07-15T12:03:34.000ZGuidance: Medical devices: list of UK approved bodieshttps://www.pharmaradar360.com/article/brief-cannara-biotech-q3-eps-cad-0-05-1c90390c9dcaf648Pharma Surgeen2026-07-15T12:01:03.000ZBRIEF-Cannara Biotech Q3 EPS CAD 0.05https://www.pharmaradar360.com/article/cannara-biotech-love-investor-presentation-summary-39d7ae2a8ad589d9Pharma Surgeen2026-07-15T11:58:57.000ZCannara Biotech (LOVE) Investor presentation Summaryhttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-clinical-trials-regulations-transitional-arrangeme-9dc39551d9dd0eb7Pharma Surgeen2026-07-15T11:54:40.000ZClinical trials for medicines: Clinical Trials Regulations transitional arrangementshttps://www.pharmaradar360.com/article/biotech-listings-back-with-a-bang-nordic-player-among-record-breaking-companies-b6eb0785bc8604fePharma Surgeen2026-07-15T11:31:07.000ZBiotech listings back with a bang – Nordic player among record-breaking companieshttps://www.pharmaradar360.com/article/legend-biotech-nasdaq-legn-reports-657m-carvykti-sales-c209dd99deb2e56aPharma Surgeen2026-07-15T11:30:38.000ZLegend Biotech (NASDAQ: LEGN) reports $657M CARVYKTI saleshttps://www.pharmaradar360.com/article/briacell-taps-fujifilm-to-make-breast-cancer-cell-therapy-ba16bf9dc4290f2aPharma Surgeen2026-07-15T11:30:00.000ZBriaCell Taps FUJIFILM to Make Breast Cancer Cell Therapyhttps://www.pharmaradar360.com/article/a16z-backed-heart-drug-biotech-braveheart-files-for-nasdaq-ipo-230dae7b6be146dePharma Surgeen2026-07-15T11:17:15.000ZA16z-Backed Heart Drug Biotech Braveheart Files for Nasdaq IPOhttps://www.pharmaradar360.com/article/jim-cramer-crowns-one-surging-sector-the-hottest-in-the-market-3481ed5d2252e0bcPharma Surgeen2026-07-15T11:17:00.000ZJim Cramer crowns one surging sector the hottest in the markethttps://www.pharmaradar360.com/article/british-sign-language-bsl-5-year-plan-department-of-health-and-social-care-30cc27cd2ce930d6Pharma Surgeen2026-07-15T11:13:31.000ZBritish Sign Language (BSL) 5-year plan: Department of Health and Social Carehttps://www.pharmaradar360.com/article/are-you-the-new-ceo-of-swiss-biotech-association-97fbb89332e16c84Pharma Surgeen2026-07-15T11:11:53.000ZAre you the new CEO of Swiss Biotech Association?https://www.pharmaradar360.com/article/top-10-hydroxy-propyl-methyl-cellulose-exporter-from-china-at-cphi-china-2026-99f80231afdaf3aePharma Surgeen2026-07-15T11:06:51.000ZTop 10 Hydroxy Propyl Methyl Cellulose Exporter from China at CPhI China 2026https://www.pharmaradar360.com/article/up-to-90-of-women-reported-better-hair-coverage-by-month-6-35d10721c905cc57Pharma Surgeen2026-07-15T11:02:16.000ZUp to 90% of women reported better hair coverage by Month 6https://www.pharmaradar360.com/article/merck-to-present-new-data-on-daily-weekly-and-monthly-options-across-its-hiv-tre-bd4ef0e000a66049Pharma Surgeen2026-07-15T11:00:00.000ZMerck to Present New Data on Daily, Weekly, and Monthly Options Across its HIV Treatment and Prevention Pipeline at AIDS 2026https://www.pharmaradar360.com/article/johnson-johnson-shares-fall-despite-better-than-expected-results-724a90bfb470a21ePharma Surgeen2026-07-15T10:56:30.000ZJohnson & Johnson shares fall despite better-than-expected resultshttps://www.pharmaradar360.com/article/astrazeneca-pays-up-to-1-5bn-to-license-dizal-pharma-s-lung-cancer-drug-7352fa87037eec86Pharma Surgeen2026-07-15T10:52:30.000ZAstraZeneca pays up to $1.5bn to license Dizal Pharma’s lung cancer drughttps://www.pharmaradar360.com/article/sichuan-kelun-biotech-biopharmaceutical-and-harbour-biomed-receive-nmpa-approval-9c99f222ca05821aPharma Surgeen2026-07-15T10:50:48.000ZSichuan Kelun-Biotech Biopharmaceutical and Harbour Biomed Receive Nmpa Approval of Ind Application for Skb575/Hbm7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/keytruda-pembrolizumab-as-monotherapy-significantly-improved-progression-free-su-50a0267f52b4a72cPharma Surgeen2026-07-15T10:45:00.000ZKEYTRUDA® (pembrolizumab) as Monotherapy Significantly Improved Progression-Free Survival (PFS) in Certain Patients With Advanced or Recurrent Endometrial Cancer With Mismatch Repair Deficient (dMMR) Tumors Compared to Chemotherapyhttps://www.pharmaradar360.com/article/biogen-shares-slide-as-diranersen-data-raise-dosing-question-00a9d85654d2a198Pharma Surgeen2026-07-15T10:42:57.000ZBiogen shares slide as diranersen data raise dosing questionhttps://www.pharmaradar360.com/article/fda-suspends-licence-of-salunkhe-vihar-road-cafe-over-hygiene-lapses-4c8b72e95af712e3Pharma Surgeen2026-07-15T10:41:38.000ZFDA suspends licence of Salunkhe Vihar Road cafe over hygiene lapseshttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-collection-verification-and-reporting-of-safety-ev-f9fb7893827ee468Pharma Surgeen2026-07-15T10:36:39.000ZClinical trials for medicines: collection, verification and reporting of safety eventshttps://www.pharmaradar360.com/article/prac-6-9-2026-b775a7fed8b8bd76Pharma Surgeen2026-07-15T10:31:50.000ZΚύρια σημεία συνεδρίασης της Επιτροπής Αξιολόγησης Κινδύνου Φαρμακοεπαγρύπνησης (PRAC), 6 – 9 Ιουλίου 2026https://www.pharmaradar360.com/article/government-and-joe-wicks-support-families-to-stay-active-514c95d4f74fc5d4Pharma Surgeen2026-07-15T10:29:24.000ZGovernment and Joe Wicks support families to stay activehttps://www.pharmaradar360.com/article/sinovac-biotech-nasdaq-sva-extends-55-per-share-dividend-deadline-7d3cd79fee7565aaPharma Surgeen2026-07-15T10:10:01.000ZSinovac Biotech (NASDAQ: SVA) extends $55 per share dividend deadlinehttps://www.pharmaradar360.com/article/corporate-report-medicines-and-healthcare-products-regulatory-agency-annual-repo-4738f50190473de0Pharma Surgeen2026-07-15T10:04:00.000ZCorporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026https://www.pharmaradar360.com/article/harbour-biomed-and-kelun-biotech-announce-nmpa-approval-of-ind-application-for-h-7c5e7d6e53eee0ccPharma Surgeen2026-07-15T10:01:00.000ZHarbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/kelun-biotech-and-harbour-biomed-announce-nmpa-approval-of-ind-application-for-s-eb7b12e2b66a8faePharma Surgeen2026-07-15T10:00:00.000ZKelun-Biotech and Harbour BioMed Announce NMPA Approval of IND Application for SKB575/HBM7575 for the Treatment of Asthmahttps://www.pharmaradar360.com/article/clinical-trials-for-medicines-modifying-a-clinical-trial-approval-4b4a6047f9614fbaPharma Surgeen2026-07-15T09:58:11.000ZClinical trials for medicines: modifying a clinical trial approvalhttps://www.pharmaradar360.com/article/a-complete-guide-to-pharmaceutical-ingredients-serum-pharma-s-apis-plant-extract-6b6ab8b530c435bbPharma Surgeen2026-07-15T09:30:00.000ZA Complete Guide to Pharmaceutical Ingredients: Serum Pharma’s APIs, Plant Extracts & Nutraceutical Solutionshttps://www.pharmaradar360.com/article/is-definium-therapeutics-inc-dftx-stock-a-biotech-opportunity-after-positive-dt1-0663c708e471fe9dPharma Surgeen2026-07-15T09:24:34.000ZIs Definium Therapeutics, Inc. (DFTX) Stock a Biotech Opportunity After Positive DT120 Depression Trial Data?https://www.pharmaradar360.com/article/pathogen-genomics-at-porton-down-a47255a8a5e18febPharma Surgeen2026-07-15T09:20:46.000ZPathogen genomics at Porton Downhttps://www.pharmaradar360.com/article/zydus-lifesciences-seals-150-million-sterling-biotech-deal-f7d126b357fa04a4Pharma Surgeen2026-07-15T09:12:42.000ZZydus Lifesciences seals $150 million Sterling Biotech dealhttps://www.pharmaradar360.com/article/dhsc-public-appointments-2026-to-2027-92f3e9c4047ba1dcPharma Surgeen2026-07-15T09:00:05.000ZDHSC public appointments: 2026 to 2027https://www.pharmaradar360.com/article/framework-agreements-between-the-department-of-health-and-social-care-and-its-ar-10908850a6438af4Pharma Surgeen2026-07-15T09:00:03.000ZFramework agreements between the Department of Health and Social Care and its arm’s length bodieshttps://www.pharmaradar360.com/article/framework-agreement-between-dhsc-and-the-uk-health-security-agency-2026-to-2029-a07733552c8962cePharma Surgeen2026-07-15T09:00:00.000ZFramework agreement between DHSC and the UK Health Security Agency: 2026 to 2029https://www.pharmaradar360.com/article/hhs-and-fda-respond-to-dea-s-action-on-kratom-related-products-a2d58e5c5f700537Pharma Surgeen2026-07-15T09:00:00.000ZHHS and FDA Respond to DEA’s Action on Kratom-Related Productshttps://www.pharmaradar360.com/article/harel-insurance-investments-financial-services-ltd-increases-position-in-teva-ph-15ed565596b69f92Pharma Surgeen2026-07-15T08:38:52.000ZHarel Insurance Investments & Financial Services Ltd. Increases Position in Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/a-new-biotech-startup-tries-to-tackle-obesity-but-not-in-the-way-you-might-expec-afdfee9cabfae5eaPharma Surgeen2026-07-15T08:34:41.000ZA new biotech startup tries to tackle obesity, but not in the way you might expecthttps://www.pharmaradar360.com/article/biotech-firm-that-went-viral-for-plans-to-create-nonsentient-humanoids-for-organ-3d03aa2c88a2b234Pharma Surgeen2026-07-15T08:34:00.000ZBiotech firm that went viral for plans to create 'nonsentient humanoids' for organ harvesting now says it was never truehttps://www.pharmaradar360.com/article/ukhsa-flusurvey-surveillance-system-9eb06a6a8ee4950aPharma Surgeen2026-07-15T08:30:13.000ZUKHSA FluSurvey surveillance systemhttps://www.pharmaradar360.com/article/notifiable-diseases-causative-agents-reports-for-2026-32900b46450305d4Pharma Surgeen2026-07-15T08:30:13.000ZNotifiable diseases: causative agents reports for 2026https://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-95d573354d6fb70dPharma Surgeen2026-07-15T08:30:13.000ZUK Clinical Research Delivery key performance indicatorshttps://www.pharmaradar360.com/article/uk-clinical-research-delivery-key-performance-indicators-data-to-june-2026-4b8ae69acc200783Pharma Surgeen2026-07-15T08:30:11.000ZUK Clinical Research Delivery key performance indicators: data to June 2026https://www.pharmaradar360.com/article/it-looks-done-common-bbq-blunders-and-how-to-avoid-them-ac5818a1039bd58aPharma Surgeen2026-07-15T08:30:11.000Z'It looks done': Common BBQ blunders and how to avoid themhttps://www.pharmaradar360.com/article/bloodborne-virus-bbv-related-infection-control-breaches-management-toolkit-1288ed113665206cPharma Surgeen2026-07-15T08:30:10.000ZBloodborne virus (BBV) related infection control breaches: management toolkithttps://www.pharmaradar360.com/article/tuberculosis-in-england-2025-report-c1ff658160421e4bPharma Surgeen2026-07-15T08:21:59.000ZTuberculosis in England, 2025 reporthttps://www.pharmaradar360.com/article/la-aemps-actualiza-su-carta-de-servicios-para-el-periodo-2026-2029-4a761197b452f87fPharma Surgeen2026-07-15T08:17:15.000ZLa AEMPS actualiza su Carta de Servicios para el periodo 2026-2029https://www.pharmaradar360.com/article/dutch-innovative-pharma-adding-8-5-billion-to-economy-7817d96798d4c09ePharma Surgeen2026-07-15T08:15:51.000ZDutch innovative pharma adding €8.5 billion to economyhttps://www.pharmaradar360.com/article/attovia-files-for-ipo-to-take-on-sanofi-and-regeneron-s-dupixent-f4d053726a21cbd8Pharma Surgeen2026-07-15T08:09:32.000ZAttovia files for IPO to take on Sanofi and Regeneron’s Dupixenthttps://www.pharmaradar360.com/article/diversify-wealth-management-llc-buys-54-488-shares-of-teva-pharmaceutical-indust-4888447e4cffe6a2Pharma Surgeen2026-07-15T07:52:32.000ZDiversify Wealth Management LLC Buys 54,488 Shares of Teva Pharmaceutical Industries Ltd. $TEVAhttps://www.pharmaradar360.com/article/i-i-startup-attovia-files-to-go-public-as-biotech-listings-momentum-builds-b612961afb583fb9Pharma Surgeen2026-07-15T07:46:00.000ZI&I startup Attovia files to go public as biotech listings momentum buildshttps://www.pharmaradar360.com/article/biotech-growth-trust-gains-19-2-in-june-outperforms-benchmark-06d44d171ad17184Pharma Surgeen2026-07-15T07:31:27.000ZBiotech Growth Trust Gains 19.2% In June, Outperforms Benchmarkhttps://www.pharmaradar360.com/article/imdylltra-becab08624a27dc1Pharma Surgeen2026-07-15T07:29:38.000ZIMDYLLTRAhttps://www.pharmaradar360.com/article/hemab-s-sutacimig-cuts-bleeds-84-in-phase-2-glanzmann-thrombasthenia-study-3d9d7d9e5d4ec704Pharma Surgeen2026-07-15T07:09:18.000ZHemab’s Sutacimig Cuts Bleeds 84% in Phase 2 Glanzmann Thrombasthenia Studyhttps://www.pharmaradar360.com/article/oric-initiates-himalayas-1-phase-3-trial-of-rinzimetostat-for-mcrpc-4ed4382f0766028fPharma Surgeen2026-07-15T07:09:18.000ZORIC Initiates Himalayas-1 Phase 3 Trial of Rinzimetostat for mCRPChttps://www.pharmaradar360.com/article/rtw-biotech-opportunities-reports-9-7-june-nav-increase-66b94ddac3f25c05Pharma Surgeen2026-07-15T07:03:49.000ZRTW Biotech Opportunities reports 9.7% June NAV increasehttps://www.pharmaradar360.com/article/formulation-freedom-in-clinical-development-why-fill2weight-matters-c2bd55340fe6b99dPharma Surgeen2026-07-15T07:00:38.000ZFormulation freedom in clinical development: Why Fill2Weight mattershttps://www.pharmaradar360.com/article/epoch-biotech-highlights-new-preclinical-data-for-apoe-christchurch-mimetic-anti-4f8bdc03ab40700bPharma Surgeen2026-07-15T07:00:00.000ZEpoch Biotech Highlights New Preclinical Data for APOE Christchurch-Mimetic Antibody at AAIC 2026 Demonstrating Favorable PK/PD and Differentiated Biomarker Approachhttps://www.pharmaradar360.com/article/kelun-biotech-s-sac-tmt-plus-pembrolizumab-hits-primary-endpoint-in-pd-l1-negati-16c13f87c3493585Pharma Surgeen2026-07-15T06:59:18.000ZKelun-Biotech’s sac-TMT Plus Pembrolizumab Hits Primary Endpoint in PD-L1-Negative NSCLChttps://www.pharmaradar360.com/article/claiming-9-77-billion-yuan-cathay-biotech-launches-large-scale-trade-secret-liti-b96e30c1aad4b3ebPharma Surgeen2026-07-15T06:47:53.000ZClaiming 9.77 billion yuan! Cathay Biotech launches large-scale trade secret litigationhttps://www.pharmaradar360.com/article/reg-rtw-biotech-opp-monthly-valuation-update-and-factsheet-474dfdce6b323116Pharma Surgeen2026-07-15T06:00:00.000ZREG - RTW Biotech Opp. - Monthly Valuation Update and Factsheethttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-maxigen-biotech-inc-twse-1783-c77d94da84761100Pharma Surgeen2026-07-15T05:55:11.000ZEnterprise value to EBITDA forward of Maxigen Biotech Inc. – TWSE:1783https://www.pharmaradar360.com/article/modulis-100-mg-ml-oral-solution-for-dogs-8-1-10-1-588ba073dccf167dPharma Surgeen2026-07-15T05:39:52.000ZΑνάκληση του κτηνιατρικού προϊόντος MODULIS 100 MG/ML ORAL SOLUTION FOR DOGS, με αρ. παρτίδων 8Β1 και 10Β1https://www.pharmaradar360.com/article/development-of-the-regenerative-medicine-product-amchepry-receives-the-10th-japa-a434e5108c8b9549Pharma Surgeen2026-07-15T05:30:00.000ZDevelopment of the Regenerative Medicine Product “AMCHEPRY” Receives the 10th Japan Bioindustry Awardhttps://www.pharmaradar360.com/article/sudan-s-embassy-in-india-hosts-roundtable-on-investment-opportunities-in-pharmac-8ea90beebe7205a6Pharma Surgeen2026-07-15T05:28:01.000ZSudan’s embassy in India hosts roundtable on investment opportunities in pharmaceutical and healthcare sectorshttps://www.pharmaradar360.com/article/from-support-to-success-joeline-moodley-s-career-journey-d8c6abd1ac9e2bb4Pharma Surgeen2026-07-15T05:25:15.000ZFrom Support to Success: Joeline Moodley’s Career Journeyhttps://www.pharmaradar360.com/article/biotech-ipos-surge-in-h1-of-2026-shattering-records-and-doubling-last-year-s-tot-d4bcff34aa0b9126Pharma Surgeen2026-07-15T05:05:29.000ZBiotech IPOs surge in H1 of 2026, shattering records and doubling last year’s totalhttps://www.pharmaradar360.com/article/why-is-tasly-pharmaceutical-stock-rallying-today-a4038067f16901ddPharma Surgeen2026-07-15T05:02:24.000ZWhy is Tasly Pharmaceutical stock rallying today?https://www.pharmaradar360.com/article/fda-grants-priority-review-to-roche-s-gazyva-gazyvaro-for-adults-with-primary-me-eb7e474db9a0bc4fPharma Surgeen2026-07-15T05:00:00.000ZFDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathyhttps://www.pharmaradar360.com/article/pharmaceutical-marketplaces-how-online-platforms-are-changing-drug-purchasing-e94755f97d7a4fbfPharma Surgeen2026-07-15T04:58:19.000ZPharmaceutical marketplaces: How online platforms are changing drug purchasinghttps://www.pharmaradar360.com/article/israel-based-ocular-disease-biotech-tarsier-pharma-ups-shares-offered-by-11-ahea-5f54dabd13484ea5Pharma Surgeen2026-07-15T04:00:00.000ZIsrael-based ocular disease biotech Tarsier Pharma ups shares offered by 11% ahead of $50 million US IPOhttps://www.pharmaradar360.com/article/brve-ipo-news-cardiovascular-diseases-biotech-braveheart-bio-files-for-a-100-mil-9369628c5511390cPharma Surgeen2026-07-15T04:00:00.000ZBRVE IPO News - Cardiovascular diseases biotech Braveheart Bio files for a $100 million IPOhttps://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-jin-yang-pharmaceutical-co-ltd-krx-007370-9526e989f10397a5Pharma Surgeen2026-07-15T03:46:09.000ZEnterprise value to EBIT forward of Jin Yang Pharmaceutical Co., Ltd. – KRX:007370https://www.pharmaradar360.com/article/price-to-earnings-forward-of-jin-yang-pharmaceutical-co-ltd-krx-007370-bc58f1ac9c6307caPharma Surgeen2026-07-15T03:12:11.000ZPrice to earnings forward of Jin Yang Pharmaceutical Co., Ltd. – KRX:007370https://www.pharmaradar360.com/article/spain-signals-new-direction-on-eu-biotech-innovation-3fa4c08cab638405Pharma Surgeen2026-07-15T02:34:31.000ZSpain signals new direction on EU biotech innovationhttps://www.pharmaradar360.com/article/maha-fda-cracks-down-on-blood-centres-suspends-34-licences-and-cancels-4-for-vio-350ea48ed20826f5Pharma Surgeen2026-07-15T02:32:09.000ZMaha FDA cracks down on blood centres, suspends 34 licences and cancels 4 for violating drug normshttps://www.pharmaradar360.com/article/study-supports-onconic-s-jaqbo-co-use-with-common-cardiovascular-drugs-0e4d0db984bb3e24Pharma Surgeen2026-07-15T02:25:51.000ZStudy supports Onconic's Jaqbo co-use with common cardiovascular drugshttps://www.pharmaradar360.com/article/biotech-visionary-john-f-crowley-to-keynote-emily-whitehead-foundation-s-2026-be-aa8c94333f503160Pharma Surgeen2026-07-15T02:24:51.000ZBiotech Visionary John F. Crowley to Keynote Emily Whitehead Foundation's 2026 Believe Ball in Philadelphiahttps://www.pharmaradar360.com/article/celltrion-ends-european-keytruda-biosimilar-trial-d9d7f6d3242fe33bPharma Surgeen2026-07-15T02:09:09.000ZCelltrion Ends European Keytruda Biosimilar Trialhttps://www.pharmaradar360.com/article/west-pharmaceutical-services-wst-enters-strategic-agreements-w-5895a90248a2b38cPharma Surgeen2026-07-15T01:27:26.000ZWest Pharmaceutical Services (WST) Enters Strategic Agreements whttps://www.pharmaradar360.com/article/fda-lets-leqembi-start-at-home-with-15-second-subcutaneous-shots-chosunbiz-69ff5749f795c132Pharma Surgeen2026-07-15T01:20:00.000ZFDA lets Leqembi start at home with 15-second subcutaneous shots - CHOSUNBIZhttps://www.pharmaradar360.com/article/is-krystal-biotech-krys-too-expensive-after-a-440-return-e46fb525191e6938Pharma Surgeen2026-07-15T01:02:24.000ZIs Krystal Biotech (KRYS) Too Expensive After A 440% Return?https://www.pharmaradar360.com/article/fda-clears-atrium-therapeutics-ind-application-for-cardiomyopathy-drug-057d8eeeec7a2cd9Pharma Surgeen2026-07-15T00:35:37.000ZFDA Clears Atrium Therapeutics' IND Application for Cardiomyopathy Drughttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-teva-advances-tev-408-is-the-stock-still-cheap-5afbbc442799b8edPharma Surgeen2026-07-15T00:16:28.000ZTeva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap?https://www.pharmaradar360.com/article/taiho-pharmaceutical-announces-the-launch-of-pi3k-inhibitor-haizexin-tablets-10m-baa20d4788ae076bPharma Surgeen2026-07-15T00:00:00.000ZTaiho Pharmaceutical Announces the Launch of PI3Kα Inhibitor HAIZEXIN® Tablets 10mg in Japanhttps://www.pharmaradar360.com/article/johnson-johnson-filed-form-8-k-8cf0b4bec32774f9Pharma Surgeen2026-07-15T00:00:00.000ZJohnson & Johnson filed Form 8-Khttps://www.pharmaradar360.com/article/gsk-filed-form-6-k-f8765a1570d7cc11Pharma Surgeen2026-07-15T00:00:00.000ZGSK filed Form 6-Khttps://www.pharmaradar360.com/article/view-all-in-depth-f57711315ba4a48ePharma Surgeen2026-07-15T00:00:00.000ZView all in-depthhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-c4e95f58a9dbd80fPharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-0fb0493ec3b1b472Pharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b91463-crore-consolidated-revenue-and-e2-82-b9517-9-crore-of-88d6731c3f7000e8Pharma Surgeen2026-07-15T00:00:00.000Znatco records %e2%82%b91463 crore consolidated revenue and %e2%82%b9517 9 crore of profit after tax for q2fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-10367a0c6e41366ePharma Surgeen2026-07-15T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-7a96393e54361fc3Pharma Surgeen2026-07-15T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-cdd057602c632224Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-12947dd97babb2e1Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-a2af2fd10ee234aaPharma Surgeen2026-07-15T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-75dab0ebd0d1d1b1Pharma Surgeen2026-07-15T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-10090283897cdeeePharma Surgeen2026-07-15T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-e859568aea77dbe9Pharma Surgeen2026-07-15T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-ae2ca742f93fe44dPharma Surgeen2026-07-15T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-9af036c1711c8eaaPharma Surgeen2026-07-15T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-6625d91ce9754161Pharma Surgeen2026-07-15T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/national-institute-on-minority-health-and-health-disparities-notice-of-partially-c5a456fd0485629cPharma Surgeen2026-07-15T00:00:00.000ZNational Institute on Minority Health and Health Disparities; Notice of Partially Closed Meetinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-f447794c7efab6fdPharma Surgeen2026-07-15T00:00:00.000ZCenter For Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/submission-for-office-of-management-and-budget-review-office-of-refugee-resettle-167423eea5e86981Pharma Surgeen2026-07-15T00:00:00.000ZSubmission for Office of Management and Budget Review; Office of Refugee Resettlement Unaccompanied Refugee Minors Program Application and Withdrawal of Unaccompanied Refugee Minors Program Application or Declination of Unaccompanied Refugee Minors Program Placement Formshttps://www.pharmaradar360.com/article/meetings-of-the-presidential-advisory-council-on-combating-antibiotic-resistant-756fbe52bcde29c3Pharma Surgeen2026-07-15T00:00:00.000ZMeetings of the Presidential Advisory Council on Combating Antibiotic-Resistant Bacteriahttps://www.pharmaradar360.com/article/request-for-information-rfi-inviting-comments-and-suggestions-on-topic-areas-for-d57f08eae827135bPharma Surgeen2026-07-15T00:00:00.000ZRequest for Information (RFI): Inviting Comments and Suggestions on Topic Areas for the NIDCR Strategic Plan for Fiscal Years 2027-2031https://www.pharmaradar360.com/article/drug-label-update-acetaminophen-extra-strength-cd3f3091fa2d9e7ePharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Acetaminophen Extra Strengthhttps://www.pharmaradar360.com/article/drug-label-update-allergy-relief-d593cd0779dcd03aPharma Surgeen2026-07-15T00:00:00.000ZDrug label update: Allergy Reliefhttps://www.pharmaradar360.com/article/mandibular-idiopathic-osteosclerosis-mimicking-inferior-alveolar-nerve-conflict-44da4b97368ffc21Pharma Surgeen2026-07-15T00:00:00.000ZMandibular idiopathic osteosclerosis mimicking inferior alveolar nerve conflicthttps://www.pharmaradar360.com/article/network-pharmacology-and-molecular-docking-identify-eugenol-as-a-lead-compound-t-672c2eca7fbeda84Pharma Surgeen2026-07-15T00:00:00.000ZNetwork pharmacology and molecular docking identify eugenol as a lead compound targeting visceral leishmaniasis pathways with nanotechnology-driven drug design and nanoscale interaction analysishttps://www.pharmaradar360.com/article/response-to-letter-to-editor-a-randomized-clinical-trial-with-unresolved-data-in-515192cbd5772e4fPharma Surgeen2026-07-15T00:00:00.000ZResponse to letter to editor: a randomized clinical trial with unresolved data integrity concernshttps://www.pharmaradar360.com/article/bilateral-pulmonary-arteriovenous-fistulas-in-a-young-patient-with-ischemic-stro-e1fa94b2c4913e14Pharma Surgeen2026-07-15T00:00:00.000ZBilateral Pulmonary Arteriovenous Fistulas in A Young Patient with Ischemic Stroke: A Case Reporthttps://www.pharmaradar360.com/article/beyond-the-classical-approach-successful-sequential-ablation-of-fast-slow-and-sl-23f3e85fdae22ad3Pharma Surgeen2026-07-15T00:00:00.000ZBeyond the Classical Approach: Successful Sequential Ablation of Fast-Slow and Slow-Fast Atrioventricular Nodal Reentrant Tachycardia. An Illustrative Casehttps://www.pharmaradar360.com/article/development-and-clinical-application-of-an-ultrasound-based-deep-learning-model-526753732ac16f94Pharma Surgeen2026-07-15T00:00:00.000ZDevelopment and clinical application of an ultrasound-based deep learning model for preoperative staging of colorectal cancerhttps://www.pharmaradar360.com/article/incidents-related-to-brachytherapy-in-the-united-states-over-the-last-10-years-68ee34ab90d3915cPharma Surgeen2026-07-15T00:00:00.000ZIncidents Related to Brachytherapy in the United States over the Last 10 Yearshttps://www.pharmaradar360.com/article/personalized-treatment-of-the-non-responder-population-the-biggest-unmet-clinica-cc75afba0d915271Pharma Surgeen2026-07-15T00:00:00.000ZPersonalized treatment of the non-responder population: The biggest unmet clinical demand in precision medicinehttps://www.pharmaradar360.com/article/feasibility-and-acceptability-of-a-group-based-telehealth-stress-management-and-373e278837b7dbaePharma Surgeen2026-07-15T00:00:00.000ZFeasibility and Acceptability of a Group-Based Telehealth Stress Management and Resilience Training Intervention for Men with Prostate Cancer on Active Surveillancehttps://www.pharmaradar360.com/article/association-between-systolic-blood-pressure-at-emergency-department-arrival-and-bfd76143da0a4bc9Pharma Surgeen2026-07-15T00:00:00.000ZAssociation Between Systolic Blood Pressure at Emergency Department Arrival and Time to Bleeding Cessation in Adult Non-Traumatic Epistaxis: A Retrospective Time-to-Event Analysishttps://www.pharmaradar360.com/article/analysis-and-implications-of-validation-results-for-a-clinical-data-based-early-c22ad35452bb9bc2Pharma Surgeen2026-07-15T00:00:00.000ZAnalysis and implications of validation results for a clinical data-based early warning model for geriatric sepsishttps://www.pharmaradar360.com/article/editorial-unlocking-cancer-s-secrets-overcoming-drug-resistance-in-cancer-stem-c-bc083b581b9775afPharma Surgeen2026-07-15T00:00:00.000ZEditorial: Unlocking cancer’s secrets: overcoming drug resistance in cancer stem cellshttps://www.pharmaradar360.com/article/drug-tolerant-persister-cells-in-lymphoid-malignancies-from-mechanisms-to-therap-e90160dd027aaacbPharma Surgeen2026-07-15T00:00:00.000ZDrug-tolerant persister cells in lymphoid malignancies: from mechanisms to therapeutic opportunitieshttps://www.pharmaradar360.com/article/clinical-phenotype-identification-based-on-inflammation-nutrition-coagulation-bi-eb1ae39074811d90Pharma Surgeen2026-07-15T00:00:00.000ZClinical phenotype identification based on inflammation–nutrition–coagulation biomarkers in advanced non-small cell lung cancerhttps://www.pharmaradar360.com/article/fourier-transform-infrared-spectroscopy-with-machine-learning-for-rapid-o-serogr-23e21c7f1a79407fPharma Surgeen2026-07-15T00:00:00.000ZFourier-transform infrared spectroscopy with machine learning for rapid O-serogrouping and typhi differentiation of clinical Salmonella isolateshttps://www.pharmaradar360.com/article/development-and-clinical-validation-of-an-artificial-intelligence-based-model-fo-e2e1fa9b121cbe42Pharma Surgeen2026-07-15T00:00:00.000ZDevelopment and clinical validation of an artificial intelligence based model for thyroid nodule malignancy risk assessment using C-TIRADS guidelineshttps://www.pharmaradar360.com/article/effect-of-tegileridine-pretreatment-on-fentanyl-induced-cough-during-general-ane-411da8f9bbcd1c4ePharma Surgeen2026-07-15T00:00:00.000ZEffect of tegileridine pretreatment on fentanyl-induced cough during general anesthesia induction: a randomized controlled trialhttps://www.pharmaradar360.com/article/diagnostic-accuracy-and-clinical-performance-of-deep-learning-models-for-grading-e554950e9894ca65Pharma Surgeen2026-07-15T00:00:00.000ZDiagnostic accuracy and clinical performance of deep learning models for grading diabetic retinopathy: a systematic review and meta-analysishttps://www.pharmaradar360.com/article/from-bench-to-bowel-translating-targeted-drug-delivery-through-gastrointestinal-19d9c4f47c29ce7aPharma Surgeen2026-07-15T00:00:00.000ZFrom bench to bowel: translating targeted drug delivery through gastrointestinal barriershttps://www.pharmaradar360.com/article/pathogenetic-significance-of-b-lymphocytes-in-various-clinical-forms-of-urogenit-31d7c04f69515980Pharma Surgeen2026-07-15T00:00:00.000ZPathogenetic Significance of B-Lymphocytes in Various Clinical Forms of Urogenital Reactive Arthritishttps://www.pharmaradar360.com/article/combined-maxillofacial-and-craniocerebral-injuries-clinical-and-statistical-anal-5ae6dabba652e0c6Pharma Surgeen2026-07-15T00:00:00.000ZCombined Maxillofacial and Craniocerebral Injuries: Clinical and Statistical Analysis and Optimization of Treatmenthttps://www.pharmaradar360.com/article/peripheral-blood-cell-counts-of-prematurely-born-small-for-gestational-age-neona-9d69f3dcb4d19ab4Pharma Surgeen2026-07-15T00:00:00.000ZPeripheral blood cell counts of prematurely born, small for gestational age neonateshttps://www.pharmaradar360.com/article/healthcare-associated-mycobacterial-port-site-infections-following-laparoscopic-b6382652751fd380Pharma Surgeen2026-07-15T00:00:00.000ZHealthcare-Associated Mycobacterial Port-Site Infections Following Laparoscopic Surgery: Clinical Characteristics and Epidemiological Evidence from a Multicenter Cohort in Bangladeshhttps://www.pharmaradar360.com/article/application-of-minics-software-in-measuring-parameters-of-femoral-neck-fractures-6512b4aa419d8983Pharma Surgeen2026-07-15T00:00:00.000ZApplication of MINICS software in measuring parameters of femoral neck fractures and its clinical significancehttps://www.pharmaradar360.com/article/advance-directives-a-literature-review-of-ethical-legal-and-clinical-aspects-ca2d9775b4e7490aPharma Surgeen2026-07-15T00:00:00.000ZADVANCE DIRECTIVES: A LITERATURE REVIEW OF ETHICAL, LEGAL, AND CLINICAL ASPECTShttps://www.pharmaradar360.com/article/retrospective-comparative-analysis-of-diffusion-tensor-and-constrained-spherical-cc7877f9a0b5e66cPharma Surgeen2026-07-15T00:00:00.000ZRetrospective Comparative Analysis of Diffusion Tensor and Constrained Spherical Deconvolution Tractography Models in a Clinical Neurosurgical Navigation Platformhttps://www.pharmaradar360.com/article/a-novel-ferro-aging-related-gene-signature-for-prognosis-and-targeted-drug-predi-355553a15cb2fb93Pharma Surgeen2026-07-15T00:00:00.000ZA Novel Ferro-Aging-Related Gene Signature for Prognosis and Targeted Drug Prediction in Cervical Cancerhttps://www.pharmaradar360.com/article/microbiota-transplant-therapy-mtt-improves-gastrointestinal-symptoms-in-children-3f76d1d66fb8510ePharma Surgeen2026-07-15T00:00:00.000ZMicrobiota Transplant Therapy (MTT) Improves Gastrointestinal Symptoms in Children with Pitt-Hopkins Syndrome: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/clinical-outcomes-of-mobile-versus-in-hospital-ecmo-a-single-center-retrospectiv-91df23842c592411Pharma Surgeen2026-07-15T00:00:00.000ZClinical outcomes of mobile versus in-hospital ECMO: A single-center retrospective cohort studyhttps://www.pharmaradar360.com/article/lar-net-a-lightweight-adaptive-receptive-field-network-for-point-cloud-segmentat-fbaa6e598ab5eb78Pharma Surgeen2026-07-15T00:00:00.000ZLAR-Net: A Lightweight Adaptive Receptive Field Network for Point Cloud Segmentation of Pharmaceutical Deposits on Reactor Inner Wallshttps://www.pharmaradar360.com/article/comparison-of-clinical-outcomes-between-femtosecond-laser-assisted-cataract-surg-f12b5de3f137a93aPharma Surgeen2026-07-15T00:00:00.000ZComparison of Clinical Outcomes Between Femtosecond Laser-assisted Cataract Surgery and Phacoemulsification in Patients with Diabetes: A Systematic Reviewhttps://www.pharmaradar360.com/article/allergic-rhinitis-in-clinical-practice-epidemiology-diagnosis-burden-and-contemp-cb24b7f6b9a7aaaePharma Surgeen2026-07-15T00:00:00.000ZAllergic rhinitis in clinical practice: Epidemiology, diagnosis, burden, and contemporary management in otorhinolaryngologyhttps://www.pharmaradar360.com/article/comparison-of-trough-only-and-peak-trough-concentration-data-for-the-calculation-094d2298f211a9fdPharma Surgeen2026-07-15T00:00:00.000ZComparison of Trough-Only and Peak–Trough Concentration Data for the Calculation of Vancomycin Area under the Concentration–Time Curve on Day 2 Using Previous and Updated Population Pharmacokinetic Modelshttps://www.pharmaradar360.com/article/proteomic-signatures-of-loss-of-glycemic-control-in-youth-onset-type-2-diabetes-0d4ba897708cba07Pharma Surgeen2026-07-15T00:00:00.000ZProteomic signatures of loss of glycemic control in youth-onset type 2 diabetes in the TODAY studyhttps://www.pharmaradar360.com/article/lipid-lowering-drugs-38ccc96c4e41242cPharma Surgeen2026-07-15T00:00:00.000ZLipid-Lowering Drugshttps://www.pharmaradar360.com/article/calcium-channel-blockers-228b3708eda51ac4Pharma Surgeen2026-07-15T00:00:00.000ZCalcium-Channel Blockershttps://www.pharmaradar360.com/article/inflammatory-and-autoimmune-diseases-eb842e43a987e491Pharma Surgeen2026-07-15T00:00:00.000ZInflammatory and Autoimmune Diseaseshttps://www.pharmaradar360.com/article/deep-vein-thrombosis-and-pulmonary-embolism-68e538e08e608336Pharma Surgeen2026-07-15T00:00:00.000ZDeep Vein Thrombosis and Pulmonary Embolismhttps://www.pharmaradar360.com/article/arrhythmias-c0ae235bf8c57668Pharma Surgeen2026-07-15T00:00:00.000ZArrhythmiashttps://www.pharmaradar360.com/article/eco-friendly-spectrophotometric-determination-of-moxifloxacin-in-pharmaceutical-de48dca599515933Pharma Surgeen2026-07-15T00:00:00.000ZEco-friendly spectrophotometric determination of moxifloxacin in pharmaceutical dosage form via ion-pair complexation with erythrosine Bhttps://www.pharmaradar360.com/article/nrgn-inhibits-cd8-t-cell-effector-function-by-downregulating-mhc-i-expression-th-d9e69596f44674a5Pharma Surgeen2026-07-15T00:00:00.000ZNRGN inhibits CD8⁺ T cell effector function by downregulating MHC-I expression through the FMR1–IRF8 axis in hepatocellular carcinomahttps://www.pharmaradar360.com/article/temporal-changes-in-clinical-practice-and-mortality-in-aneurysmal-subarachnoid-h-daeb2ac01515c803Pharma Surgeen2026-07-15T00:00:00.000ZTemporal changes in clinical practice and mortality in aneurysmal subarachnoid hemorrhage following the 2012 AHA/ASA guidelines: a retrospective cohort study using the MIMIC databasehttps://www.pharmaradar360.com/article/histone-lysine-methyltransferases-kmt2c-and-kmt2d-join-the-all-star-tumor-suppre-f7dfd7c61e5d7e88Pharma Surgeen2026-07-15T00:00:00.000ZHistone lysine methyltransferases KMT2C and KMT2D join the all-star tumor suppressor team in gastrointestinal cancerhttps://www.pharmaradar360.com/article/targeting-hepatic-cholesterol-sensing-to-tackle-metabolic-dysfunction-associated-5b3618c89b2f06cdPharma Surgeen2026-07-15T00:00:00.000ZTargeting hepatic cholesterol sensing to tackle metabolic dysfunction–associated steatohepatitishttps://www.pharmaradar360.com/article/gut-microbe-derived-short-chain-fatty-acids-regulate-alphavirus-arthritis-and-ma-de7de1f1051b2880Pharma Surgeen2026-07-15T00:00:00.000ZGut microbe–derived short-chain fatty acids regulate alphavirus arthritis and macrophage activation in micehttps://www.pharmaradar360.com/article/branched-chain-amino-acid-metabolism-and-microbiome-in-adolescents-with-obesity-d9f9c355c1db3589Pharma Surgeen2026-07-15T00:00:00.000ZBranched chain amino acid metabolism and microbiome in adolescents with obesity during weight loss therapyhttps://www.pharmaradar360.com/article/figure-3-from-car-t-cell-kinetics-persistence-and-clinical-outcomes-in-adult-pat-3d0904d8caff3470Pharma Surgeen2026-07-15T00:00:00.000ZFigure 3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/figure-5-from-car-t-cell-kinetics-persistence-and-clinical-outcomes-in-adult-pat-f77ba97c7bce08d1Pharma Surgeen2026-07-15T00:00:00.000ZFigure 5 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/supplementary-table-s3-from-car-t-cell-kinetics-persistence-and-clinical-outcome-fde6a3539eccd0b2Pharma Surgeen2026-07-15T00:00:00.000ZSupplementary Table S3 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/supplementary-table-s6-from-car-t-cell-kinetics-persistence-and-clinical-outcome-c8951be6c287e311Pharma Surgeen2026-07-15T00:00:00.000ZSupplementary Table S6 from CAR T-cell Kinetics, Persistence, and Clinical Outcomes in Adult Patients with Relapsed/Refractory B-cell ALL Treated with Obecabtagene Autoleucel in the FELIX Studyhttps://www.pharmaradar360.com/article/enhancing-clinical-diagnosis-of-amyotrophic-lateral-sclerosis-through-advanced-p-7f2028da2c685acdPharma Surgeen2026-07-15T00:00:00.000ZEnhancing Clinical Diagnosis of Amyotrophic Lateral Sclerosis Through Advanced Prediction and Analysis Using Deep Learninghttps://www.pharmaradar360.com/article/types-i-ii-v-and-vi-secretion-system-genes-in-clinical-uropathogenic-i-escherich-6d51714c67aeb5c1Pharma Surgeen2026-07-15T00:00:00.000ZTypes I, II, V, and VI secretion system genes in clinical uropathogenic <i>Escherichia coli</i> associate with antibiotic susceptibility, biofilm formation, and persister cellshttps://www.pharmaradar360.com/article/photo-quiz-a-parsimonious-explanation-for-stacked-coins-3a31d67a739301f3Pharma Surgeen2026-07-15T00:00:00.000ZPhoto Quiz: A parsimonious explanation for stacked coinshttps://www.pharmaradar360.com/article/combined-left-atrial-appendage-closure-and-pulmonary-vein-re-isolation-in-very-h-ac6c03cf58e21365Pharma Surgeen2026-07-15T00:00:00.000ZCombined Left Atrial Appendage Closure and Pulmonary Vein Re‐Isolation in Very‐High Stroke‐Risk Patientshttps://www.pharmaradar360.com/article/a-retrospective-cohort-study-on-clinical-presentation-and-surgical-management-of-be018f3836cf4a57Pharma Surgeen2026-07-15T00:00:00.000ZA retrospective cohort study on clinical presentation and surgical management of rectal prolapse at a tertiary care centerhttps://www.pharmaradar360.com/article/comparative-evaluation-of-siemens-atellica-and-abbott-architect-tacrolimus-immun-b6f0030e455e219fPharma Surgeen2026-07-15T00:00:00.000ZComparative Evaluation of Siemens Atellica and Abbott ARCHITECT Tacrolimus Immunoassays Against LC-MS/MS: A Short Communicationhttps://www.pharmaradar360.com/article/comment-on-the-reliability-and-smallest-detectable-difference-of-the-severity-of-e4c1c35e6de5bfebPharma Surgeen2026-07-15T00:00:00.000ZComment on ‘The reliability and smallest detectable difference of the Severity of Alopecia Tool score in alopecia areata’https://www.pharmaradar360.com/article/ketamine-versus-propofol-for-sedation-in-acute-psychiatric-emergencies-during-ae-318d3bf216d7fa32Pharma Surgeen2026-07-15T00:00:00.000ZKetamine Versus Propofol for Sedation in Acute Psychiatric Emergencies During Aeromedical Retrieval: A Randomized Clinical Trialhttps://www.pharmaradar360.com/article/an-in-vivo-study-on-extended-release-formulation-of-buprenorphine-in-sprague-daw-90644077fb0a8f2aPharma Surgeen2026-07-15T00:00:00.000ZAn in vivo Study on Extended-Release Formulation of Buprenorphine in Sprague-Dawley Ratshttps://www.pharmaradar360.com/article/effectiveness-and-cost-effectiveness-of-digital-approaches-for-training-frontlin-d9cdf4f6c4902c6fPharma Surgeen2026-07-15T00:00:00.000ZEffectiveness and cost-effectiveness of digital approaches for training frontline health workers in depression care: a randomized controlled trialhttps://www.pharmaradar360.com/article/modular-in-vivo-antibody-adc-click-to-reverse-drug-resistance-in-tumours-df51cea37e8bf31fPharma Surgeen2026-07-15T00:00:00.000ZModular in vivo antibody–ADC click to reverse drug resistance in tumourshttps://www.pharmaradar360.com/article/pharmaceutical-cocrystals-of-febuxostat-design-fabrication-characterization-and-c9e0ffc66c926544Pharma Surgeen2026-07-15T00:00:00.000ZPharmaceutical Cocrystals of Febuxostat: Design, Fabrication, Characterization and Bioavailability Assessmenthttps://www.pharmaradar360.com/article/current-evidence-on-the-core-components-of-the-geriatric-rehabilitation-process-c0829ed60f851749Pharma Surgeen2026-07-15T00:00:00.000ZCurrent evidence on the core components of the geriatric rehabilitation process: a systematic reviewhttps://www.pharmaradar360.com/article/plant-growth-promotion-of-rice-oryza-sativa-l-with-root-endophytic-bacteria-isol-536af6b7e134ac3cPharma Surgeen2026-07-15T00:00:00.000ZPlant growth promotion of rice (Oryza sativa L.) with root endophytic bacteria, isolated from wild Solanaceous medicinal plants Solanum nigrum L., Solanum sisymbriifolium Lam., and Solanum virginianum L.https://www.pharmaradar360.com/article/microbial-inoculation-enhances-salt-tolerance-by-modulating-secondary-metabolite-b8a6050b368f862aPharma Surgeen2026-07-15T00:00:00.000ZMicrobial inoculation enhances salt tolerance by modulating secondary metabolites and key biosynthetic genes in Melissa officinalishttps://www.pharmaradar360.com/article/matrine-suppresses-thymoma-stemness-and-apoptosis-via-yth-n6-methyladenosine-rna-c94e4de681d1dac9Pharma Surgeen2026-07-15T00:00:00.000ZMatrine suppresses thymoma stemness and apoptosis via YTH N6-methyladenosine RNA binding protein 1 and Wnt/β-catenin signalinghttps://www.pharmaradar360.com/article/her2-positive-rectal-adenocarcinoma-metastatic-to-the-pancreas-complicated-by-ob-85892179bf8ec779Pharma Surgeen2026-07-15T00:00:00.000ZHER2-positive rectal adenocarcinoma metastatic to the pancreas complicated by obstructive pancreatitis and an infected pseudocyst: a case reporthttps://www.pharmaradar360.com/article/agrp-reflects-glucocorticoid-action-integrated-experimental-and-clinical-evidenc-1e2ce43c1e8f1f99Pharma Surgeen2026-07-15T00:00:00.000ZAgRP reflects glucocorticoid action: integrated experimental and clinical evidencehttps://www.pharmaradar360.com/article/the-apelin-apj-axis-in-heart-failure-mechanistic-insights-clinical-evidence-and-7411cb6629142213Pharma Surgeen2026-07-15T00:00:00.000ZThe Apelin-APJ Axis in Heart Failure: Mechanistic Insights, Clinical Evidence, and Translational Challengeshttps://www.pharmaradar360.com/article/real-world-evaluation-of-primary-prophylactic-use-of-granulocyte-colony-stimulat-77067d0759237640Pharma Surgeen2026-07-15T00:00:00.000ZReal-world evaluation of primary prophylactic use of granulocyte colony-stimulating factor in patients with metastatic castration-sensitive prostate cancer treated with triplet therapyhttps://www.pharmaradar360.com/article/correlation-between-mri-disc-morphology-and-temporomandibular-joint-osteoarthrit-d3c85bb45d1b8af4Pharma Surgeen2026-07-15T00:00:00.000ZCorrelation between MRI disc morphology and temporomandibular joint osteoarthritis in patients with temporomandibular joint disc displacement with reduction: a cross-sectional CBCT-MRI combined studyhttps://www.pharmaradar360.com/article/letter-to-the-editor-re-deep-learning-models-for-lumbar-spinal-stenosis-on-mri-m-0a0820ce9e4b5321Pharma Surgeen2026-07-15T00:00:00.000ZLetter to the Editor Re: “Deep learning models for lumbar spinal stenosis on MRI: model comparison and clinical benchmarking” by Lee et al. (Eur Spine J [2026] 35:548–558. DOI: 10.1007/s00586-025-09443-2)https://www.pharmaradar360.com/article/timosaponin-aiii-based-liposomes-loaded-with-auranofin-for-the-induction-of-ferr-e6f4e03cb2ee172bPharma Surgeen2026-07-15T00:00:00.000ZTimosaponin AIII-based liposomes loaded with Auranofin for the induction of ferroptosis in anaplastic thyroid carcinomahttps://www.pharmaradar360.com/article/a-misaligned-multi-modal-clinical-time-series-representation-learning-framework-d6de250d3492a962Pharma Surgeen2026-07-15T00:00:00.000ZA Misaligned Multi-modal Clinical Time Series Representation Learning Framework for In-Hospital Mortality Predictionhttps://www.pharmaradar360.com/article/ugca-dti-uncertainty-gated-cross-attention-for-robust-drug-target-interaction-pr-b9deafb6c9e3303bPharma Surgeen2026-07-15T00:00:00.000ZUGCA-DTI: Uncertainty-Gated Cross-Attention for Robust Drug–Target Interaction Predictionhttps://www.pharmaradar360.com/article/an-interactive-web-server-for-multi-model-drug-repositioning-and-evidence-tracin-604d01fe2cff5a73Pharma Surgeen2026-07-15T00:00:00.000ZAn Interactive Web Server for Multi-model Drug Repositioning and Evidence Tracinghttps://www.pharmaradar360.com/article/predicting-drug-synergy-via-cross-modal-contrastive-learning-and-masked-multi-om-16216e23fd710908Pharma Surgeen2026-07-15T00:00:00.000ZPredicting Drug Synergy via Cross-modal Contrastive Learning and Masked Multi-omics Hypergraphshttps://www.pharmaradar360.com/article/the-expression-patterns-of-antibody-drug-conjugate-related-markers-in-urothelial-00b0c48e66cfe232Pharma Surgeen2026-07-15T00:00:00.000ZThe Expression Patterns of Antibody–Drug Conjugate‐Related Markers in Urothelial Carcinoma With Histological Variantshttps://www.pharmaradar360.com/article/anatomy-curriculum-and-teaching-insights-from-medical-students-in-the-united-kin-fc561d126754ce3fPharma Surgeen2026-07-15T00:00:00.000ZAnatomy Curriculum and Teaching Insights From Medical Students in the United Kingdom: A National Surveyhttps://www.pharmaradar360.com/article/nct07706335-insulin-resistance-and-its-association-with-no-reflow-phenomenon-aft-39a80ec969bc16f1Pharma Surgeen2026-07-15T00:00:00.000ZNCT07706335: Insulin Resistance and Its Association With no Reflow Phenomenon After Primary PCI in Type II Diabetic STEMI Patients.https://www.pharmaradar360.com/article/nct07705737-rademikibart-iv-for-acute-asthma-and-copd-exacerbation-2f3baddc9faf323fPharma Surgeen2026-07-15T00:00:00.000ZNCT07705737: Rademikibart IV for Acute Asthma and COPD Exacerbationhttps://www.pharmaradar360.com/article/nct07705620-a-behavioral-digital-intervention-for-parkinson-s-disease-040343a4af2968d9Pharma Surgeen2026-07-15T00:00:00.000ZNCT07705620: A Behavioral Digital Intervention For Parkinson's Diseasehttps://www.pharmaradar360.com/article/nct07705607-a-clinical-trial-of-mk-8748-compared-to-aflibercept-in-participants-c4abf9a0e6618274Pharma Surgeen2026-07-15T00:00:00.000ZNCT07705607: A Clinical Trial of MK-8748 Compared to Aflibercept in Participants With Diabetic Macular Edema (MK-8748-005)https://www.pharmaradar360.com/article/nct07705321-assessment-of-retinal-microcirculation-in-patients-with-type-1-diabe-d4f09baf700fa1a7Pharma Surgeen2026-07-15T00:00:00.000ZNCT07705321: Assessment of Retinal Microcirculation in Patients With Type 1 Diabetes Mellitushttps://www.pharmaradar360.com/article/nct07705100-clinical-feasibility-study-of-upright-low-dose-high-resolution-3d-br-da7911ee39a317b7Pharma Surgeen2026-07-15T00:00:00.000ZNCT07705100: Clinical Feasibility Study of Upright, Low-dose, High-resolution, 3D Breast CT (UBCT).https://www.pharmaradar360.com/article/nct07704749-fitbit-tracked-micromovement-for-cardiometabolic-health-in-rural-wom-2dfe8092c3874338Pharma Surgeen2026-07-15T00:00:00.000ZNCT07704749: Fitbit-Tracked Micromovement for Cardiometabolic Health in Rural Womenhttps://www.pharmaradar360.com/article/nct07704658-pralsetinib-ddi-study-in-patients-with-advanced-or-metastatic-solid-7469132dedcdd77aPharma Surgeen2026-07-15T00:00:00.000ZNCT07704658: Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumorshttps://www.pharmaradar360.com/article/nct07704177-phase-ii-study-of-trastuzumab-rezetecan-combined-with-adebrelimab-an-995bc3e91d8ba893Pharma Surgeen2026-07-15T00:00:00.000ZNCT07704177: Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancerhttps://www.pharmaradar360.com/article/nct07704047-a-clinical-study-of-ft1-in-patients-with-short-bowel-syndrome-2fbfa483b7dbc752Pharma Surgeen2026-07-15T00:00:00.000ZNCT07704047: A Clinical Study of FT1 in Patients With Short Bowel Syndromehttps://www.pharmaradar360.com/article/nct07703176-clinical-and-radiographic-assessment-of-first-permanent-molars-with-a59b8f0c1c62818aPharma Surgeen2026-07-15T00:00:00.000ZNCT07703176: Clinical and Radiographic Assessment of First Permanent Molars With Cention-Nhttps://www.pharmaradar360.com/article/nct07692841-single-dose-vs-divided-dose-g-csf-for-stem-cell-mobilization-in-heal-ea150d25a6ceb2baPharma Surgeen2026-07-15T00:00:00.000ZNCT07692841: Single-Dose vs. Divided-Dose G-CSF for Stem Cell Mobilization in Healthy Allogeneic Donorshttps://www.pharmaradar360.com/article/nct07686380-il-15-superagonist-with-or-without-vaccine-in-biochemically-recurren-cfd5e39e4ab2fd00Pharma Surgeen2026-07-15T00:00:00.000ZNCT07686380: IL-15 Superagonist With or Without Vaccine in Biochemically Recurrent Prostate Cancer After Previous Stereotactic Body Radiation Therapyhttps://www.pharmaradar360.com/article/nct07657624-modifiable-risk-factors-for-cognitive-dysfunction-in-patients-with-c-817e8b0a1914b719Pharma Surgeen2026-07-15T00:00:00.000ZNCT07657624: Modifiable Risk Factors for Cognitive Dysfunction in Patients With Coronary Heart Diseasehttps://www.pharmaradar360.com/article/nct07568249-changes-in-oral-health-related-quality-of-life-ohrqol-during-full-ar-23abbd43294c7c96Pharma Surgeen2026-07-15T00:00:00.000ZNCT07568249: Changes in Oral Health-related Quality of Life (OHRQoL) During Full Arch Implant Treatmenthttps://www.pharmaradar360.com/article/nct07463443-effectiveness-of-chatbot-for-improving-caregiving-outcomes-in-primar-81d0ec560e8d39b9Pharma Surgeen2026-07-15T00:00:00.000ZNCT07463443: Effectiveness of Chatbot for Improving Caregiving Outcomes in Primary Caregivers of Geriatric Pneumonia Patients: A Study on Knowledge, Attitude and Practice.https://www.pharmaradar360.com/article/nct07460882-the-impact-of-low-sodium-salt-substitute-use-on-serum-potassium-leve-440a88b315e5f1b3Pharma Surgeen2026-07-15T00:00:00.000ZNCT07460882: The Impact of Low Sodium Salt Substitute Use on Serum Potassium Levels Among Patients With Hypertensionhttps://www.pharmaradar360.com/article/nct07202104-improvement-of-an-algorithm-to-detect-structural-heart-murmurs-in-ad-89401cd76e8ab89bPharma Surgeen2026-07-15T00:00:00.000ZNCT07202104: Improvement of an Algorithm to Detect Structural Heart Murmurs in Adult Patients Using Electronic Stethoscopeshttps://www.pharmaradar360.com/article/nct07182721-skb264-plus-inetetamab-in-her2-positive-metastatic-breast-cancer-pat-f10afdbbad96c54ePharma Surgeen2026-07-15T00:00:00.000ZNCT07182721: SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd Treatmenthttps://www.pharmaradar360.com/article/nct07024615-a-study-of-asp2138-given-before-surgery-then-chemotherapy-after-surg-15ab81b50f5a7065Pharma Surgeen2026-07-15T00:00:00.000ZNCT07024615: A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancerhttps://www.pharmaradar360.com/article/nct06948110-deciphering-the-genetic-architecture-of-autoimmune-diseases-353665cab37b522aPharma Surgeen2026-07-15T00:00:00.000ZNCT06948110: Deciphering the Genetic Architecture of Autoimmune Diseaseshttps://www.pharmaradar360.com/article/nct06817460-a-clinical-study-comparing-the-effectiveness-and-safety-of-two-surgi-163806ba42808db6Pharma Surgeen2026-07-15T00:00:00.000ZNCT06817460: A Clinical Study Comparing the Effectiveness and Safety of Two Surgical Pathways for Laparoscopic Total Hysterectomyhttps://www.pharmaradar360.com/article/nct06781931-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-c5d13c492ec2f906Pharma Surgeen2026-07-15T00:00:00.000ZNCT06781931: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct06780046-study-that-will-evaluate-the-brazilian-population-with-copd-f3d28068db4e6acePharma Surgeen2026-07-15T00:00:00.000ZNCT06780046: Study That Will Evaluate the Brazilian Population With COPD.https://www.pharmaradar360.com/article/nct06764316-a-first-in-human-study-to-learn-about-the-safety-of-bay-3547926-and-eca0f5f2bd909ce6Pharma Surgeen2026-07-15T00:00:00.000ZNCT06764316: A First-in-human Study to Learn About the Safety of BAY 3547926 and How Well it Works in Participants With Advanced Liver Cancerhttps://www.pharmaradar360.com/article/nct06662058-remote-audiometry-to-monitor-for-treatment-related-hearing-loss-in-p-a7f1275ace4689fePharma Surgeen2026-07-15T00:00:00.000ZNCT06662058: Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiationhttps://www.pharmaradar360.com/article/nct06595940-genetic-analysis-of-uncommon-disease-presentations-in-non-us-populat-9a7defcdd77feca2Pharma Surgeen2026-07-15T00:00:00.000ZNCT06595940: Genetic Analysis of Uncommon Disease Presentations in Non-US Populationshttps://www.pharmaradar360.com/article/nct06587295-intramuscular-acm-cpg-monotherapy-in-patients-with-advanced-metastat-01178fce32b2f70bPharma Surgeen2026-07-15T00:00:00.000ZNCT06587295: Intramuscular ACM-CpG Monotherapy in Patients With Advanced/Metastatic Solid Tumors With Prior Response to Immunotherapy Alone or in Combination With Chemotherapyhttps://www.pharmaradar360.com/article/nct06465368-a-study-to-learn-about-the-study-medicine-pf-07220060-together-with-4936764a07b06b52Pharma Surgeen2026-07-15T00:00:00.000ZNCT06465368: A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopausehttps://www.pharmaradar360.com/article/nct06264180-vo-and-nivolumab-vs-physician-s-choice-in-advanced-melanoma-that-pro-62f107ebe3ba4301Pharma Surgeen2026-07-15T00:00:00.000ZNCT06264180: VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]https://www.pharmaradar360.com/article/nct06084208-assessment-of-diagnostic-yield-using-a-robotic-navigational-bronchos-3dc1ddf53c58e385Pharma Surgeen2026-07-15T00:00:00.000ZNCT06084208: Assessment of Diagnostic Yield Using a Robotic Navigational Bronchoscopy System With CBCThttps://www.pharmaradar360.com/article/nct06042725-mc210808-venetoclax-in-combination-with-lenalidomide-and-dexamethaso-2f04680882536c3dPharma Surgeen2026-07-15T00:00:00.000ZNCT06042725: MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myelomahttps://www.pharmaradar360.com/article/nct05853367-study-of-mk-0472-in-participants-with-advanced-metastatic-solid-tumo-96dc8d04ebd31226Pharma Surgeen2026-07-15T00:00:00.000ZNCT05853367: Study of MK-0472 in Participants With Advanced/Metastatic Solid Tumors (MK-0472-001)https://www.pharmaradar360.com/article/nct05800015-a-trial-to-learn-how-the-combination-of-fianlimab-with-cemiplimab-an-fefed22380bd216aPharma Surgeen2026-07-15T00:00:00.000ZNCT05800015: A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct05594043-a-study-of-mk-6598-as-monotherapy-and-in-combination-with-pembrolizu-7ebb8bf18c696982Pharma Surgeen2026-07-15T00:00:00.000ZNCT05594043: A Study of MK-6598 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-6598-001)https://www.pharmaradar360.com/article/nct05342597-clinical-pharmacology-study-of-oral-edaravone-in-healthy-adult-subje-3eeb4eea6261cc5dPharma Surgeen2026-07-15T00:00:00.000ZNCT05342597: Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Subjects (Food Effect Study)https://www.pharmaradar360.com/article/nct05260268-technology-enabled-strategies-to-promote-treatment-adherence-in-live-07439b714a2362eaPharma Surgeen2026-07-15T00:00:00.000ZNCT05260268: Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplanthttps://www.pharmaradar360.com/article/nct05039632-phase-i-ii-randomized-study-of-nbtxr3-activated-by-abscopal-or-radsc-6e9dbd3a36c3eb23Pharma Surgeen2026-07-15T00:00:00.000ZNCT05039632: Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancieshttps://www.pharmaradar360.com/article/nct04837040-a-study-to-evaluate-the-safety-and-efficacy-of-paltusotine-for-the-t-c5913a4abceef36fPharma Surgeen2026-07-15T00:00:00.000ZNCT04837040: A Study to Evaluate the Safety and Efficacy of Paltusotine for the Treatment of Acromegalyhttps://www.pharmaradar360.com/article/nct04029090-a-study-to-evaluate-the-effect-of-mci-186-at-therapeutic-and-supra-t-f26b86a7c93a2937Pharma Surgeen2026-07-15T00:00:00.000ZNCT04029090: A Study to Evaluate the Effect of MCI-186 at Therapeutic and Supra-Therapeutic Doses on the QT Interval(QT)/Corrected QT Interval(QTc) Interval in Healthy Subjectshttps://www.pharmaradar360.com/article/nct04014348-geospatial-analysis-of-neighborhood-environmental-stress-in-relation-e4f549f7a3e0ed3fPharma Surgeen2026-07-15T00:00:00.000ZNCT04014348: Geospatial Analysis of Neighborhood Environmental Stress in Relation to Biological Markers of Cardiovascular Health and Health Behaviors in Womenhttps://www.pharmaradar360.com/article/nct03891446-long-term-safety-and-efficacy-extension-trial-of-bimatoprost-sr-cd5105b623096870Pharma Surgeen2026-07-15T00:00:00.000ZNCT03891446: Long-term Safety and Efficacy Extension Trial of Bimatoprost SRhttps://www.pharmaradar360.com/article/nct03172689-validation-of-cardioq-versus-picco-in-children-752c42d699c024d1Pharma Surgeen2026-07-15T00:00:00.000ZNCT03172689: Validation of CardioQ Versus PiCCO in Childrenhttps://www.pharmaradar360.com/article/nct02760849-surgery-in-preventing-ovarian-cancer-in-patients-with-genetic-mutati-a4e05a9f8ff1a3abPharma Surgeen2026-07-15T00:00:00.000ZNCT02760849: Surgery in Preventing Ovarian Cancer in Patients With Genetic Mutationshttps://www.pharmaradar360.com/article/nct02276443-molecular-testing-and-imaging-in-improving-response-in-patients-with-f22566c4561d0b41Pharma Surgeen2026-07-15T00:00:00.000ZNCT02276443: Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiativehttps://www.pharmaradar360.com/article/nct01934660-links-between-inflammation-and-cardiometabolic-diseases-cbdc4127a143ca47Pharma Surgeen2026-07-15T00:00:00.000ZNCT01934660: Links Between Inflammation and Cardiometabolic Diseaseshttps://www.pharmaradar360.com/article/nct01900132-electrical-impedance-myography-natural-history-studies-inneuromuscul-4e262bdc8f5dcc6bPharma Surgeen2026-07-15T00:00:00.000ZNCT01900132: Electrical Impedance Myography: Natural History Studies inNeuromuscular Disorders and Healthy Volunteershttps://www.pharmaradar360.com/article/nct01631617-effects-of-treatments-on-atopic-dermatitis-87ad1d45bd50a362Pharma Surgeen2026-07-15T00:00:00.000ZNCT01631617: Effects of Treatments on Atopic Dermatitishttps://www.pharmaradar360.com/article/nct01621581-aav2-gdnf-for-advanced-parkinson-s-disease-0df7c70891e59c45Pharma Surgeen2026-07-15T00:00:00.000ZNCT01621581: AAV2-GDNF for Advanced Parkinson s Diseasehttps://www.pharmaradar360.com/article/nct01371630-inotuzumab-ozogamicin-and-combination-chemotherapy-in-treating-patie-fd01d55795bf1cd5Pharma Surgeen2026-07-15T00:00:00.000ZNCT01371630: Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemiahttps://www.pharmaradar360.com/article/nct00501826-combination-chemotherapy-and-nelarabine-in-treating-patients-with-t-7c826bf5a3d1a914Pharma Surgeen2026-07-15T00:00:00.000ZNCT00501826: Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphomahttps://www.pharmaradar360.com/article/nct00001467-genetic-analysis-of-immune-disorders-64d622071b2f208aPharma Surgeen2026-07-15T00:00:00.000ZNCT00001467: Genetic Analysis of Immune Disordershttps://www.pharmaradar360.com/article/otsuka-group-introduces-its-first-battery-energy-storage-system-in-hokkaido-aims-a6dabe7ee5ababa0Pharma Surgeen2026-07-15T00:00:00.000ZOtsuka Group Introduces Its First Battery Energy Storage System in Hokkaido —Aims to Maximize Renewable Energy Use and Stabilize Power Supply in Order to Promote Business Growth and Environmental Initiatives—https://www.pharmaradar360.com/article/erasca-eras-surges-8-9-on-encouraging-cancer-trial-results-c588ba98a6e05dd8Pharma Surgeen2026-07-14T23:40:45.000ZErasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Resultshttps://www.pharmaradar360.com/article/kelun-biotech-announces-phase-iii-study-of-sacituzumab-tirumotecan-sac-tmt-in-co-7ba056ff9e7e079fPharma Surgeen2026-07-14T23:30:00.000ZKelun-Biotech Announces Phase III Study of Sacituzumab Tirumotecan (sac-TMT) in Combination with Pembrolizumab as First-Line Treatment for PD-L1-Negative Non-Squamous NSCLC Met Primary Endpointhttps://www.pharmaradar360.com/article/dothan-named-hub-for-15m-biotech-project-cdde5d84ccd9cc25Pharma Surgeen2026-07-14T22:57:32.000ZDothan Named Hub for $15M Biotech Projecthttps://www.pharmaradar360.com/article/asu-callan-jmb-partner-to-boost-alabama-s-workforce-and-pharmaceutical-industry-c5db822667ceb8bdPharma Surgeen2026-07-14T22:47:07.000ZASU, Callan JMB Partner to Boost Alabama’s Workforce and Pharmaceutical Industryhttps://www.pharmaradar360.com/article/lessons-learned-on-commercializing-an-allogeneic-t-cell-therapy-202f2c37220690baPharma Surgeen2026-07-14T22:16:45.000ZLessons Learned on Commercializing an Allogeneic T Cell Therapyhttps://www.pharmaradar360.com/article/becky-jackson-curran-advocates-for-accessibility-and-understanding-b775105ac7d94180Pharma Surgeen2026-07-14T20:53:32.000ZBecky Jackson Curran Advocates for Accessibility and Understandinghttps://www.pharmaradar360.com/article/invesco-healthcare-etf-vs-vaneck-biotech-which-etf-will-deliver-the-healthiest-r-3339ce11d3479df4Pharma Surgeen2026-07-14T20:41:00.000ZInvesco Healthcare ETF vs VanEck Biotech: Which ETF Will Deliver the Healthiest Returns for 2026?https://www.pharmaradar360.com/article/oric-pharmaceuticals-announces-initiation-of-himalayas-1-phase-3-trial-in-mcrpc-c54d18e356d798dfPharma Surgeen2026-07-14T20:26:44.000ZORIC® Pharmaceuticals Announces Initiation of Himalayas-1 Phase 3 Trial in mCRPC Evaluating Rinzimetostat in Combination with NUBEQA® (Darolutamide), Supported by Clinical Collaboration with Bayerhttps://www.pharmaradar360.com/article/drug-alerts-and-statements-65b7066201a76f64Pharma Surgeen2026-07-14T20:14:42.000ZDrug Alerts and Statementshttps://www.pharmaradar360.com/article/petition-asks-fda-to-implement-new-oem-rule-for-mri-safety-35caf55636450b44Pharma Surgeen2026-07-14T20:11:48.000ZPetition asks FDA to implement new OEM rule for MRI safetyhttps://www.pharmaradar360.com/article/bayer-will-provide-nubeqa-at-no-cost-for-oric-s-global-trial-448b8f0cde54dc6aPharma Surgeen2026-07-14T20:05:00.000ZBayer Will Provide NUBEQA at No Cost for ORIC’s Global Trial